Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Low doses of
interferon alfa may be as effective as high doses.
PURPOSE: Randomized phase III trial to compare the effectiveness of low-dose or high-dose
interferon alfa in treating patients who have newly diagnosed chronic myelogenous leukemia.